CD45RA Antibody (158-4D3)

CD45 (leukocyte common antigen), the most common hematopoietic lineage marker, is a transmembrane glycoprotein tyrosine phosphatase with important roles in immune system signal transduction pathways. Antibody panels have been instrumental in identifying multiple isoforms, including CD45RA. Isoforms differ in their extracellular domain and are generated by alternative splicing of exons 4, 5 and 6 encoding peptide segments called A, B, and C, respectively. At least five different isoforms have been identified in humans: containing all three (ABC), two (AB and BC), one (B) or no (O) exons. A given antibody recognizes either every isoform (CD45 antibody) or only a subset (restricted CD45R antibody). The CD45RA 158-4D3 antibody clone reacts with the ABC and BC isoforms (Schlossman et al, 1995). CD45RA has a molecular weight of 205-220 kDa.
Isoform expression is regulated in lymphocyte type and activation-state dependent manners. CD45RA is expressed on subsets of T and B cells rendering the CD45RA antibody particularly useful for studying subpopulations. For example, naive T lymphocytes express CD45RA containing the A exon which is lost after activation and replaced by CD45R0. In this regard, the CD45RA antibody is a useful naive T cells marker since they express CD45RA, and activated or memory T cells are CD45RA negative and CD45RO positive (Schlossman et al, 1995). CD45RA is differentially expressed on lymphomas and the CD45RA antibody may also be used to help identify or classify lymphomas such as the CD45RA positive B from the CD45R0 positive T cell lymphomas. Researchers are encouraged to consult the scientific literature for additional information about CD45RA expression, including the use of antibody panels that include a CD45RA antibody for characterizing a given malignancy.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: IHC-P.

Showing Publications 1 - 3 of 3.

Publications using NBP2-15193	Applications	Species
Jiang S, Ding X, Wu Q et al. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer Frontiers in immunology 2022-08-11 [PMID: 36032097] (IHC-P, Human) Details: Lot 5788-2P200827	IHC-P	Human
Perugino CA, Kaneko N, Maehara T et al. CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease J. Allergy Clin. Immunol. 2020-05-30 [PMID: 32485263]
Mahalingam M, Pozniak A, McManus TJ et al. Abnormalities of CD45 isoform expression in HIV infection. Clin Immunol Immunopathol. 1996-11-01 [PMID: 8906753]

Array NBP2-15193

• CD45RA Antibodies